Surgery
FASN for diffuse malignant peritoneal mesothelioma: a prognostic biomarker after CRS+HIPEC and a therapeutic target
Journal of Translational Medicine 2026 May 21 [Link] Valentina Doldi, Chiara Maura Ciniselli, Claudia Aurelio, Enrica Favini, Silvio Marco Veronese, Fabio Bozzi, Shigeki Kusamura, Dario Baratti, Silvia Martini, Paolo Verderio, Marcello Deraco, Marco Folini, Paolo Gandellini, Sandro Pasquali, Nadia Zaffaroni Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive malignancy with limited…
Read MoreQuantitative MRI-Based T Category in Pleural Mesothelioma: Analysis of a Large Real-World Cohort
Academic Radiology 2026 May 15 [Link] Ritu R Gill, William G Richards, Emanuele Mazzola, Beow Y Yeap, Raphael Bueno Abstract Rationale and objectives: Accurate clinical staging in pleural mesothelioma (PM) is limited by the subjectivity of conventional imaging assessment, which introduces inter- and intraobserver variability. Tumor volume, pleural thickness and diaphragmatic thickness measurements individually prognostic…
Read MorePIPAC for Malignant Peritoneal Mesothelioma: Current Insights and Future Directions
Digestive Surgery 2026 May 12 [Link] Arianna Castagna, Aphrodite Fotiadou, Ali Ramouz, Preslava Gesheva, Niall Brindl, Wiebke Solass, Andreas Brandl Abstract Malignant peritoneal mesothelioma (MPM) is a rare and aggressive tumour with poor prognosis, often diagnosed late due to nonspecific symptoms. Current standard treatment involves systemic chemotherapy and cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy…
Read MoreImpact of a national mesothelioma network on outcomes including survival
Thorax 2026 May 8 [Link] Matthew Tate, Joshua Joseph Roche, Selina Tsim, Neil McGlinchey, Katie Ferguson, Phil Reid, Philip Short, Mahendran Chetty, Clinton Ali, Noelle O’Rourke, Carol MacGregor, Carolyn MacRae, Laura McNaughton, Rebecca Bloomfield, Tracey Petrie, Susan Smyth, Jennifer Latham, Lynne Hunter, Rocco Bilancia, Alan Kirk, Craig Dick, Fiona Roberts, Elaine MacDuff, Jill Slavin, Hemamalini…
Read MoreReal-world outcomes of multimodal treatment for pleural mesothelioma: A retrospective study in a high-volume integrated regional center
JTCVS Open 2026 January 30 [Link] Alison S Baskin, Keza Levine, Yun-Yi Hung, Elaine Liang, Kian C Banks, J Marie Suga, Jeffrey B Velotta Abstract Objective: To evaluate overall survival (OS) associated with multimodal treatment regimens, including pleurectomy/decortication (PD) and systemic therapy, in patients with clinical stage I-II epithelioid pleural mesothelioma (PM). Methods: We identified…
Read MoreImmunotherapy resistance and strategies in malignant pleural mesothelioma
Cancer Drug Resistance 2026 March 26 [Link] Wanyi Xia, Yulong Zhang, Juanzhi Zhao, Xiaoli Tan, Shaolong Ju, Wei Zou, Chaoqun Chen, Chunwei Li, Yanghua Xu, Yingming Peng, Shengqiao Li Abstract Malignant pleural mesothelioma (MPM) remains one of the most aggressive thoracic malignancies, characterized by profound resistance to conventional modalities such as surgery, chemotherapy, and radiotherapy,…
Read MoreThe Society of Thoracic Surgeons 2026 Expert Consensus on the Multimodal Treatment of Pleural Mesothelioma
The Annals of Thoracic Surgery 2026 July [Link] Jeffrey B Velotta, Anja C Roden, Jonathan Rice, Charles B Simone, Bansari Upadhyay, Pallavi Sood, Daniel L Miller, R Taylor Ripley, Andrea Wolf, Bryan M Burt, Samuel S Kim, Isabelle Opitz, Hedy L Kindler, Harvey I Pass, J W Awori Hayanga, Valerie Rusch, Raphael Bueno Abstract Background:…
Read MoreThe Importance of 5-hmC Expression Loss in Diagnosis of Mesothelioma and the Relationship Between TROP2 Expression and Histomorphological Parameters in Mesotheliomas
International Journal of Surgical Pathology 2026 April 6 [Link] Hale Kivrak, İlke Evrim Secinti, Egemen Akincioglu, Elcin Kadan, Ertugrul Celik, Gulcin Guler Simsek Abstract Objectives: Mesothelioma is an aggressive cancer that is often not suitable for curative surgery. It can be difficult to distinguish from reactive processes and other malignancies, especially in small biopsies, and outcomes of systemic therapies remain…
Read MorePhase 1/1b study of direct intratumoral injection of pleural mesothelioma of immunostimulant prior to surgical resection
The Journal of Thoracic and Cardiovascular Surgery 2026 March 24 [Link] Andrea S Wolf, Shubham Gulati, Komal Dolasia, Bailey Fitzgerald, Jorge Gomez, David Yankelevitz, Andres Salazar, Alexander M Tsankov, Thomas Marron, Raja Flores Abstract Objective: To evaluate the role of neoadjuvant injection of the viral mimic poly-ICLC (polyinosinic-polycytidylic acid-poly-l-lysine carboxymethylcellulose) in patients with pleural mesothelioma…
Read MorePhase 1/1b study of direct intratumoral injection of pleural mesothelioma of immunostimulant prior to surgical resection
The Journal of Thoracic & Cardiovascular Surgery 2026 March 24 [Link] Andrea S Wolf, Shubham Gulati, Komal Dolasia, Bailey Fitzgerald, Jorge Gomez, David Yankelevitz, Andres Salazar, Alexander M Tsankov, Thomas Marron, Raja Flores Abstract Objective: To evaluate the role of neoadjuvant injection of the viral mimic poly-ICLC (polyinosinic-polycytidylic acid-poly-l-lysine carboxymethylcellulose) in patients with pleural mesothelioma…
Read More
Skip to content